Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Registration Number
- NCT05998941
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT05997342
- Locations
- 🇨🇳
West China hospital, Sichuan university, Chengdu, Sichuan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 380
- Registration Number
- NCT05994365
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Tianjin People's Hospital, Tianjin, Tianjin, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT05987358
- Locations
- 🇨🇳
Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Tangshan People's Hospital, Tangshan, Hebei, China
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05987371
- Locations
- 🇨🇳
Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China
🇨🇳Wuhan Sixth Hospital, Wuhan, Hubei, China
🇨🇳People's Hospital of Jiangxi province, Nanchang, Jiangxi, China
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 412
- Registration Number
- NCT05985187
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Sun Yat-sen University Cancer Prevention Center, Guangzhou, Guangdong, China
🇨🇳Affiliated cancer hospital of harbin medical university, Harbin, Heilongjiang, China
To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05982106
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05975645
- Locations
- 🇨🇳
Affiliated hospital of zunyi medical university, Zunyi, Guizhou, China
🇨🇳Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳The First People's Hospital of Shangqiu City, Shangqiu, Henan, China
A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05970432
- Locations
- 🇨🇳
The third xiangya hospital of central south university, Changsha, Hunan, China
🇨🇳Renmin Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT05959694
- Locations
- 🇨🇳
Anqing Municipal Hospital, Anqing, Anhui, China
🇨🇳Gansu province Wuwei tumour hospital, Wuwei, Gansu, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China